Introduction {#S1}
============

Male breast cancer (MBC) is a rare disease that occurs in \~0.2% of all neoplasms among men. There are currently only single case reports in the literature that describe the diagnostics and treatment of male breast cancer \[[@ref1]-[@ref5]\]. The European Organization for Research and Treatment of Cancer (EORTC), Translational Breast Cancer Research Consortium (10085/TBCRC) / Breast International Group (BIG) / North American Breast Cancer Groups (NABCG) International Male Breast Cancer Programme revealed that MBC presents usually as luminal A like subtype, 88% of cases express androgen receptors, only 1% are triple negative, and 9% are HER-2positive \[[@ref6]\]. Males that harbor the *BRCA1* gene mutation have a higher risk of developing breast cancer (1%). The risk of male breast cancer is also higher in males with the *BRCA2* gene mutation (7%) \[[@ref7]\]. Cases of male breast cancer are more common in *BRCA2* than *BRCA1* families. Prostate cancer is a recognized component of the hereditary breast and ovarian cancer (HBOC) syndrome tumor spectrum, where inherited susceptibility is accounted for by mutations in *BRCA1* and *BRCA2*. The overall risk of prostate cancer has been reported as up to 3.8-fold for men who carry *BRCA1* mutations, and up to 8.6-fold for men who carry *BRCA2* mutations. Mutations in *BRCA2* have been associated with more aggressive clinicopathological characteristics of prostate cancer and worse outcomes.

The predominant histological subtype (\> 80%) of male breast cancer is invasive ductal carcinoma. Lobular carcinoma is rare \[[@ref7]\]. Histopathological features of male breast cancer are: intermediate or high histological grade (G2-G3), estrogen receptor (ER) positive (90%), progesterone receptor (PR) positive (80-96%) and human epidermal growth factor receptor 2 (HER2) negative (\~15% of MBCs exhibited upregulated HER2 expression), expression of androgen receptors (range 39-95%) \[[@ref8]-[@ref10]\]. Breast cancer types in males are primarily invasive ductal carcinoma with higher stage and lower grade, and are more often ER+ and HER2- subtypes in comparison with woman with breast cancer. MBCs exhibit worse prognosis than female breast cancer due to the often advanced stage at diagnosis, higher age and frequent presence of comorbidities \[[@ref11]\].

There are three founder alleles of *BRCA1* (c.181T\>G, c.4034delA and c.5266dupC) that were reported in Poland in 2000, and these three mutations have comprised the standard testing panel used throughout the country. Since that time, new original mutations (c.68_69delAG, c.676del, c.3700_3704delGTAAA, c.3756_3759delGTCT and c.5251C\>T) have been described. Certain recurrent mutations of *BRCA2* have also been reported (c.658_659delGT, c.3847_3848delGT, c.5239_5240insT, c.5946delT and c.7913_7917del) in Polish families \[[@ref12]\].

According to the BIG database, c.2808_2811del ACAA p. (p.Ala938Profs) is the second most reported frameshift *BRCA2* mutation and the most prevalent mutation in Spain \[[@ref13]\]. This mutation has been reported in almost all Western European countries \[[@ref14]\] and in African women with premenopausal breast cancer \[[@ref15]\]. The detected mutation has already been described twice in the Polish population, and is also the third most common pathogenic mutation in *BRCA2* in the Caucasian population. It is believed that the high frequency of this mutation is associated with its location in the "hot spot of the mutation" (mutational hot spot) \[[@ref16]\]. The coexistence of the c.2808_2811delACAA mutation with MBC has already been described \[[@ref17]\].

The present paper reports the case of a 75-year-old man who was diagnosed with a locally advanced invasive ductal carcinoma and with family history of breast cancer (two daughters with breast cancer aged 46 and 38 years). The aim of the present study was to evaluate the presence of c.2808_2811del ACAA (p.Ala938Profs) *BRCA2* mutation in MBC and to assess the association between the aforementioned mutation and clinicopathological factors.

Case report {#S2}
===========

A 75-year-old patient was admitted to the Genetic Outpatient Clinic in Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, with a diagnosis of right breast cancer and with a family history of cancer (two daughters who were diagnosed with breast cancer at ages 46 and 38 years). In the physical examination, a tumor was detected in the central area of the right breast that was 4 cm × 4 cmin size, engaging the nipple and infiltrating its base. In the right axillary plane, a lymph node was examined with dimensions of 1.5 cm × 2.0 cm. Other regional lymph nodes were not enlarged. On 11 January, 2018, PET testing was performed. The PET/CT scan demonstrated the presence of right breast cancer (tumor sized 28 mm × 23 mm) with metastasis in the right armpit (lymph node sized 10 mm × 5 mm). A thick-needle biopsy was performed. Histopathological examination revealed ductal invasive carcinoma. On 19 February, 2018, a radical amputation of the right breast with lymphadenectomy was performed. Postoperative histopathological examination demonstrated a tumor with the presence of angioinvasion, without neuroinvasion, pT2 N1a Mx, NST NG-3 G-3, Ki-67 75%, ER (+++), PR (+++), and without upregulated HER2 expression. Metastases were demonstrated in two of 40 lymph nodes. The metastatic lymph nodes were up to 0.5 cm in diameter with transgression of the nodal sac.

The patient was qualified for adjuvant chemotherapy with AC regimens, and then for radiotherapy and hormonotherapy based on aromatase inhibitors. Genetic counseling was also performed. During the genetic consultation, a family history was collected, the pedigree was removed and the medical records were reviewed. The patient provided written informed consent regarding the use of his biological material for clinical research (all were routine laboratory analyses). The complete coding sequence of the *BRCA1* and *BRCA2* genes was analyzed on the genomic DNA material using next generation sequencing (NGS) on the Ion Torrent platform. The c.2808_2811delACAA p. (Ala938Profs) mutation was observed in the *BRCA2* gene. The presence of the c.2808_2811delACAA p. (Ala938Profs) mutation in the *BRCA2* gene was confirmed using the Sanger method. The detected mutation causes a frameshift mutation, resulting in the creation of an additional translation termination codon and the synthesis of an abnormal protein. Genetic consultation with subsequent genetic testing was recommended for adult family members. Cancer was present in the patient's family history, with his two daughters both having developed breast cancer. One daughter was diagnosed aged 41 in 2010. She received radical amputation of the right breast with lymphadenectomy. Histopathological examination revealed ductal invasive carcinoma, pT2pN2, ER (++), PR (+++) and HER2 that was not upregulated. She was qualified for adjuvant chemotherapy with FAC regimens, and then for radiotherapy and hormonotherapy based on tamoxifen. Genetic counseling was also performed. The tested material had genomic DNA isolated from peripheral venous blood. No c.68_69delAG, c.181T\>G, c.4034delA, c.5266dupC or c.3700_3704del5 mutations were detected in the *BRCA1* gene (reference sequence number GenBank NM_007294.3), or c.5946delT and c.9403delC in the *BRCA2* gene. Test methods included restriction fragment length polymorphism-PCR for mutations in c.181T\>G (*BRCA1*) and c.9403delC (*BRCA2*); and allele-specific amplification PCR for other mutations (*BRCA1*). The second daughter was diagnosed aged 38 years in 2014. She had left breast cancer type cT4bN3M0. A thick-needle biopsy was performed. Histopathological examination revealed lobular invasive carcinoma G2, ER (+), PR (+), HER2 that was not upregulated. She had neoadjuvant chemotherapy with AC and paclitaxel regimens, and then hormonotherapy based on tamoxifen. On 8 August, 2014, numerous metastases in the CNS were detected in the CT scan of the head. She received radiotherapy, and genetic counseling was also performed. No c.68_69delAG, c.181T\>G, c.4034delA, c.5266dupC and c.3700_3704del5 mutations were observed in the *BRCA1* gene (reference sequence number GenBank NM_007294.3), or c.5946delT and c.9403delC in the *BRCA2* gene. There were also no mutations observed in the *CHEK2* gene (c.1100delC and mutation c.470T\>C) (GenBank NM_145862.2.). However, the presence of the c.2808_2811delACAA (p.Ala938Profs) mutation in the *BRCA2* gene was confirmed using the Sanger method; the same mutation was reported in her father.

Conclusions {#S3}
===========

The presence of the c.2808_2811delACAA (p.Ala938-Profs) mutation in the *BRCA2* gene was associated with a diagnosis at a later age, a higher histological degree, a higher mitotic index (Ki-67), a positive steroid receptor status, the luminal B subtype and HER2- breast cancer. This mutation is also associated with higher predisposition to hereditary breast cancer.

NGS improved the detection rates of mutations in Polish patients with familial breast cancer. NGS-based testing should be performed in patients with breast or ovarian cancer who present with *BRCA1*/*2* negative tests for the selected *BRCA1*/*2* pathogenic mutations.

Disclosure {#S4}
==========

The authors report no conflict of interest.
